scholarly journals Integrated Analysis Reveals That Long Non-Coding RNA TUBA4B Can Be Used as a Prognostic Biomarker in Various Cancers

2018 ◽  
Vol 49 (2) ◽  
pp. 530-544 ◽  
Author(s):  
Ting Zhang ◽  
Dong-ming Wu ◽  
Shi-hua Deng ◽  
Rong Han ◽  
Teng Liu ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Prognostic Biomarker ◽  
Meta Analysis ◽  
Normal Lung ◽  
Integrated Analysis ◽  
Tumor Type ◽  
Free Survival ◽  
Non Coding Rna ◽  
Tumor Tissues ◽  
Long Non Coding Rna

Background/Aims: Recent studies have reported the importance of tubulin alpha 4b (TUBA4B), a long non-coding RNA, in the development of several cancers; however, studies on its clinical significance are rare. In the present meta-analysis, we investigated whether TUBA4B can be used as a prognostic biomarker in human cancers. Methods: A comprehensive search was performed in PubMed, Embase, Web of Science, and the Gene Expression Omnibus databases. Hazard ratios from individual studies were calculated and pooled using a random-effects or fix-effects model. The pooled hazard ratio (HR) with 95% confidence interval (CI) was used to evaluate the value of TUBA4B. The expression of TUBA4B was evaluated in lung cancer tissue arrays by fluorescence in situ hybridization assay. Additionally, a sensitivity analysis and Begg’s test were conducted. Results: We found that TUBA4B was significantly correlated with overall survival (OS) (HR = 1.33, 95% CI: 1.16–1.52, P=0.000), disease-free survival (DFS; HR = 1.25, 95% CI: 1.06–1.48, P=0.007), and recurrence-free survival (RFS; HR = 1.42, 95% CI: 1.26–1.60, P=0.000). In addition, TUBA4B was a risk factor for lung cancer (HR = 1.24, 95% CI: 1.03–1.49, P=0.021), colon cancer (HR = 1.67, 95% CI: 1.02–2.74, P=0.042), breast cancer (HR = 1.52, 95% CI: 1.10–2.12, P=0.012), and ovarian cancer (HR = 1.67, 95% CI: 1.18–2.36, P=0.004). Moreover, LncRNA-TUBA4B was significantly lower expression in tumor tissues than normal lung tissues (P< 0.001). The expression of lncRNA-TUBA4B was decreased with the progression of lung cancer stage. A subgroup meta-analysis based on data resource, sample size, region, patient numbers, and tumor type was further performed. Our studies revealed that tumor tissues with low levels of TUBA4B was significantly associated with short OS, DFS, and RFS in cancer patients. Conclusion: The present findings suggest that TUBA4B can be a novel biomarker for the prognosis of various cancers.

Long non-coding RNA CRNDE as a potential prognostic biomarker in solid tumors: A meta-analysis

2018 ◽  
Vol 481 ◽  
pp. 99-107 ◽  
Author(s):  
Chaojie Liang ◽  
Bing Zhang ◽  
Hua Ge ◽  
Yingchen Xu ◽  
Guangming Li ◽  
...  
Keyword(s):  
Solid Tumors ◽  
Prognostic Biomarker ◽  
Meta Analysis ◽  
Non Coding Rna ◽  
Long Non Coding Rna

The prognostic value of long non-coding RNA PlncRNA-1 in patients with cancers: a systematic review and meta-analysis

2020 ◽  
Author(s):  
Lijun Lei ◽  
Lianbing Sheng ◽  
Lingyuan Wu ◽  
Jiaojing Liu ◽  
Bin Wei ◽  
...  
Keyword(s):  
Web Of Science ◽  
Prognostic Biomarker ◽  
Meta Analysis ◽  
Database Search ◽  
Clinical Prognosis ◽  
Non Coding Rna ◽  
Increased Risk ◽  
Cancer Types ◽  
The Relationship ◽  
Long Non Coding Rna

Abstract Background We performed this meta-analysis to elucidate whether the expression of PlncRNA-1 might serve as an effective prognostic marker for various cancers. Methods We conducted a database search of PubMed, ScienceDirect, Embase, Web of Science and CNKI database (up to Oct 31, 2019). The pooled hazard ratio (HR), odds ratio (OR) and 95% confidence interval (CI) were used to estimate the strength of the relationship between PlncRNA-1 expression and the clinical prognosis of cancer patients. Results The results showed that elevated PlncRNA-1 expression predicted a poor OS with pooled HRs of 1.43 (95% CI: 1.25-1.63, I 2 =63.1%, P=0.004). Likewise, we found that advanced tumour stages were associated with upregulated PlncRNA-1 expression in various cancer types (III–IV vs I–II: OR=2.79, 95% CI: 1.76-4.41, I 2 =0%, P=0.822),patients with high PlncRNA-1 expression might have an increased risk of large tumours (OR=2.03, 95% CI: 1.31-3.14, I 2 =67.1%, P=0.028). Conclusions PlncRNA-1 might be used as a prognostic biomarker and as a tool for the early detection of various tumours.

scholarly journals An eight-long non-coding RNA signature as a candidate prognostic biomarker for lung cancer

2016 ◽  
Vol 36 (1) ◽  
pp. 215-222 ◽  
Author(s):  
ZHENBO TU ◽  
DU HE ◽  
XINZHOU DENG ◽  
MENG XIONG ◽  
XIAOXING HUANG ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Prognostic Biomarker ◽  
Non Coding Rna ◽  
Long Non Coding Rna ◽  
Rna Signature

scholarly journals Long non-coding RNA TUG1 as a potential prognostic biomarker in human cancers: a meta-analysis

Oncotarget ◽  
2017 ◽  
Vol 8 (37) ◽  
pp. 62454-62462 ◽  
Author(s):  
Peng-Ju Ma ◽  
Qing-Kai Guan ◽  
Lei Meng ◽  
Nan Qin ◽  
Jia Zhao ◽  
...  
Keyword(s):  
Prognostic Biomarker ◽  
Meta Analysis ◽  
Human Cancers ◽  
Non Coding Rna ◽  
Long Non Coding Rna

The utility of long non-coding RNA ZEB1-AS1 as a prognostic biomarker in human solid tumors: A meta-analysis

2018 ◽  
Vol 485 ◽  
pp. 14-20 ◽  
Author(s):  
Xue-liang Zuo ◽  
Juan Cai ◽  
Zhi-qiang Chen ◽  
Yao Zhang ◽  
Lin-hu Liang ◽  
...  
Keyword(s):  
Solid Tumors ◽  
Prognostic Biomarker ◽  
Meta Analysis ◽  
Non Coding Rna ◽  
Human Solid Tumors ◽  
Long Non Coding Rna

scholarly journals Long non-coding RNA HULC as a potential prognostic biomarker in human cancers: a meta-analysis

Oncotarget ◽  
2017 ◽  
Vol 8 (13) ◽  
pp. 21410-21417 ◽  
Author(s):  
Yang-Hua Fan ◽  
Miao-Jing Wu ◽  
Yuan Jiang ◽  
Minhua Ye ◽  
Shi-Gang Lu ◽  
...  
Keyword(s):  
Prognostic Biomarker ◽  
Meta Analysis ◽  
Human Cancers ◽  
Non Coding Rna ◽  
Long Non Coding Rna

Long non coding RNA CCAT2 enhances proliferation, invasion and drug-resistances of non-small lung cancer via activating the miR-204-3p-suppresed IGFBP2/AKT/Bcl2 pathway

2020 ◽  
Author(s):  
Zheng Wang ◽  
Rongjie Yang ◽  
Yu Liu ◽  
Yanfeng Huang
Keyword(s):  
Lung Cancer ◽  
Drug Resistance ◽  
Theoretical Basis ◽  
High Rate ◽  
Aberrant Expression ◽  
Efficient Treatment ◽  
Non Coding Rna ◽  
Tumor Tissues ◽  
Underlying Mechanisms ◽  
Long Non Coding Rna

Abstract Background The treatment efficacy remains unsatisfactory due to the rapid progress, high rate of metastasis, and drug-resistance of NSCLS. It has been demonstrated that aberrant expression of long non coding RNA colon cancer-associated transcript 2 (CCAT2) in cells was closely related to tumorigenesis, tumor metastasis, and development of drug-resistance. The present study was aimed to thoroughly investigate the effect of CCAT2 in the growth of NSCLC and the underlying mechanisms, so that provide valuable theoretical basis for efficient treatment of NSCLC. Methods The expressions of CCAT2 and its target genes and downstream signals were respectively determined by Western-blot assay and RT-qPCR experiment. Cell growth of NSCLC cells was investigated using the CCK-8 kit while the proliferation assay was performed with the help of EDU staining. The NSCLC-bearing mice mode was established to evaluate the effect of PYCR1 on the progress of NSCLC and the underlying mechanisms in vivo. Results The CCAT2 was highly expressed in NSCLC tumor tissues and cells while not the corresponding normal ones. Further studies revealed that aberrant expression of CCAT2 in lung cancer signally contributed to proliferation, invasion, and migration of cancer cells and the progress of tumor tissues. Moreover, high level of CCAT2 dramatically down-regulated the cytotoxicity of cisplatin (DDP) to NSCLC cells and tissues by upregulation of the drug-resistance related proteins. Mechanisms studies displayed that upregulation of CCAT2 markedly decreased the miR-204-3p while contrary result was obtained when down-regulated the CCAT2 level. We further demonstrated that down-regulation of miR-204-3p level signally enhanced the activity of the insulin-like growth factor (IGF) signaling pathway. Conclusions The CCAT2 promoted the progress and drug-resistance of NSCLC thorough activation of the miR-204-3p suppressed IGFBP2/AKT/Bcl2 pathway, and may provide theoretical basis for improvement of therapy of NSCLC.

Sign in / Sign up

Export Citation Format

Share Document